-DOCSTART- -X- O
Influenza -X- _ O
viruses -X- _ O
are -X- _ O
a -X- _ O
major -X- _ O
threat -X- _ O
to -X- _ O
human -X- _ O
health -X- _ O
globally. -X- _ O
In -X- _ O
addition -X- _ O
to -X- _ O
further -X- _ O
improving -X- _ O
vaccine -X- _ O
prophylaxis -X- _ O
, -X- _ O
disease -X- _ O
management -X- _ O
through -X- _ O
antiviral -X- _ B-Intervention
therapeutics -X- _ I-Intervention
constitutes -X- _ O
an -X- _ O
important -X- _ O
component -X- _ O
of -X- _ O
the -X- _ O
current -X- _ O
intervention -X- _ O
strategy -X- _ O
to -X- _ O
prevent -X- _ O
advance -X- _ O
to -X- _ O
complicated -X- _ O
disease -X- _ O
and -X- _ O
reduce -X- _ O
case-fatality -X- _ O
rates. -X- _ O
Standard-of-care -X- _ O
is -X- _ O
treatment -X- _ O
with -X- _ O
neuraminidase -X- _ B-Intervention
inhibitors -X- _ I-Intervention
that -X- _ O
prevent -X- _ B-Outcome
viral -X- _ I-Outcome
dissemination. -X- _ I-Outcome
In -X- _ O
2018 -X- _ O
, -X- _ O
the -X- _ O
first -X- _ O
mechanistically -X- _ O
new -X- _ O
influenza -X- _ O
drug -X- _ O
class -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
uncomplicated -X- _ O
seasonal -X- _ O
influenza -X- _ O
in -X- _ O
2 -X- _ O
decades -X- _ O
was -X- _ O
approved -X- _ O
for -X- _ O
human -X- _ O
use. -X- _ O
Targeting -X- _ O
the -X- _ O
PA -X- _ O
endonuclease -X- _ O
subunit -X- _ O
of -X- _ O
the -X- _ O
viral -X- _ O
polymerase -X- _ O
complex -X- _ O
, -X- _ O
this -X- _ O
class -X- _ O
suppresses -X- _ O
viral -X- _ O
replication. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
genetic -X- _ O
barrier -X- _ O
against -X- _ O
viral -X- _ O
resistance -X- _ O
to -X- _ O
both -X- _ O
drug -X- _ O
classes -X- _ O
is -X- _ O
low -X- _ O
, -X- _ O
pre-existing -X- _ O
resistance -X- _ O
is -X- _ O
observed -X- _ O
in -X- _ O
circulating -X- _ O
strains -X- _ O
, -X- _ O
and -X- _ O
resistant -X- _ O
viruses -X- _ O
are -X- _ O
pathogenic -X- _ O
and -X- _ O
transmit -X- _ O
efficiently. -X- _ O
Addressing -X- _ O
the -X- _ O
resistance -X- _ O
problem -X- _ O
has -X- _ O
emerged -X- _ O
as -X- _ O
an -X- _ O
important -X- _ O
objective -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
next-generation -X- _ O
influenza -X- _ O
virus -X- _ O
therapeutics. -X- _ O
This -X- _ O
review -X- _ O
will -X- _ O
discuss -X- _ O
the -X- _ O
status -X- _ O
of -X- _ O
influenza -X- _ O
therapeutics -X- _ O
including -X- _ O
the -X- _ O
endonuclease -X- _ B-Intervention
inhibitor -X- _ I-Intervention
baloxavir -X- _ I-Intervention
marboxil -X- _ I-Intervention
after -X- _ O
its -X- _ O
first -X- _ O
year -X- _ O
of -X- _ O
clinical -X- _ O
use -X- _ O
and -X- _ O
evaluate -X- _ O
a -X- _ O
subset -X- _ O
of -X- _ O
direct-acting -X- _ O
antiviral -X- _ O
candidates -X- _ O
in -X- _ O
different -X- _ O
stages -X- _ O
of -X- _ O
preclinical -X- _ O
and -X- _ O
clinical -X- _ O
development -X- _ O
. -X- _ O

